GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » Beta

Cynata Therapeutics (ASX:CYP) Beta : 0.90 (As of Jun. 10, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-10), Cynata Therapeutics's Beta is 0.90.


Cynata Therapeutics Beta Historical Data

The historical data trend for Cynata Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics Beta Chart

Cynata Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.27 1.01 1.03 0.87 0.83

Cynata Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.87 0.82 0.83 1.03

Competitive Comparison of Cynata Therapeutics's Beta

For the Biotechnology subindustry, Cynata Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cynata Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's Beta falls into.



Cynata Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Cynata Therapeutics  (ASX:CYP) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Cynata Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Cynata Therapeutics (ASX:CYP) Business Description

Traded in Other Exchanges
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines